Testimony on behalf of Formycon regarding irreparable harm in biosimilar case
In Regeneron Pharmaceuticals v. Formycon, Arun Sharma testified on behalf of defendant Formycon regarding irreparable harm and other injunction factors in connection with Regeneron's motion for a preliminary injunction to block a biosimilar version of Regeneron's Eylea®.